Beta-4-containing neuronal nicotinic acetylcholine receptor (β4* nAChR) (β4* nAChR)

Beta-4-containing neuronal nicotinic acetylcholine receptor (β4* nAChR) is a pentameric ligand-gated ion channel primarily composed of the β4 subunit in combination with α3 and α5 subunits (UniProt P30926). These receptors are predominantly expressed in the autonomic ganglia and the adrenal medulla, where they mediate fast excitatory synaptic transmission (PubMed: 21835188). In the central nervous system, they are localized within the medial habenula and interpeduncular nucleus, forming a circuit that regulates nicotine consumption and withdrawal (PubMed: 23041528). Genetic variations within the CHRNA5-CHRNA3-CHRNB4 gene cluster are strongly associated with nicotine dependence and the risk of developing lung cancer (NIH: Gene ID 1143). Pharmacological agents such as varenicline and cytisine interact with these receptors as partial agonists to modulate reward pathways and assist in smoking cessation (PubChem: CID 5310966). Selective antagonists like 18-methoxycoronaridine are being investigated for their potential to treat various substance use disorders by targeting the α3β4 subtype (PubMed: 15695164). Because of their high density in the peripheral nervous system, drugs targeting β4* nAChRs often carry risks of autonomic side effects, including cardiovascular instability and gastrointestinal distress (PubMed: 17030507). Overall, these receptors represent a critical target for understanding the neurobiology of addiction and developing more specific therapeutic interventions.

Other names

CHRNB4nAChR beta 4Neuronal acetylcholine receptor subunit beta-4α3β4 nicotinic receptorCHRNB4-containing nAChR

Ligand-gated ion channel modulation (agonism, antagonism, or partial agonism) leading to changes in membrane potential and intracellular calcium levels.